Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70490 ↗At a glance
Metaanalyse in Alimentary Pharmacology & Therapeutics, 2026. Written by Shiva Poola and 4 co-authors. Institution: Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Brody School of Medicine, East Carolina University/ECU Health Medical C…. Major MEDLINE topics: Rituximab, Virus Activation, Hepatitis B Antibodies, Hepatitis B virus. Cited 4 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti‐CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti‐HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti‐HBs) titer have a higher level of protection against reactivation.
Aim
The purpose of this study was to systematically review the role of anti‐HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.
Methods
We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolved HBV infection, defined as HBsAg negative and anti‐HBc positive, which discussed anti‐HBs titer. The search was conducted in PubMed, Embase via Elsevier, Scopus, and Cochrane CENTRAL inclusive July 2025. We evaluated the incidence of HBV reactivation from cohort studies that described anti‐HBs categorically based on anti‐HBs titer: ‘negative’ (titer < 10 iU/L), ‘10–100 iU/L’, or ‘> 100 iU/L’. Meta‐analysis statistics describe the proportion and risk difference for different anti‐HBs levels.
Results
The overall reactivation rate was 12.6%. There was a significant difference in HBV reactivation depending on titer: anti‐HBs negative 27.3% (51/195) (20.0%–36.0%), titer < 100 iU/L 13.8% (47/379) (8.8%–20.8%), and titer > 100 iU/L 3.5% (8/339) (1.8%–6.9%).
Conclusions
Those with anti‐HBs titer > 100 iU/L can be considered lower risk for HBV reactivation and may not require antiviral therapy, but monitoring with initiation of antiviral therapy if titer falls below 100 iU/L.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Brody School of Medicine, East Carolina University/ECU Health Medical Center, Greenville, North Carolina, USA.
- Research Librarian for the Health Sciences, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.
- Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.
ORCID profiles: Kerry Sewell
Cite
APA
Poola, S., Kratzer, M., Sewell, K., Yang, Z., & Tillmann, H. L. (2026). Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70490
Vancouver
Poola S, Kratzer M, Sewell K, Yang Z, Tillmann HL. Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70490
BibTeX
@article{Poola2026,
author = {Poola, Shiva and Kratzer, MaryKate and Sewell, Kerry and Yang, Zikun and Tillmann, Hans L},
title = {Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70490}
}
EUVIMED